CHF Technologies, Inc., d/b/a BioVentrix, San Ramon, California, announced today the appointment of Warren E. Pinckert II and Michael N. Taglich to the Company’s Board of Directors.
Mr. Pinckert was formerly President and CEO of Cholestech Corporation, where he raised three rounds of public financing and guided the company through its recent acquisition. Previously, as a Director of PacifiCare (UNH - a NYSE health maintenance company), he served as a member of the Compensation and Special Opportunities Committees, and was Chairman of PacifiCare’s Audit Committee. Mr. Pinckert also served as CFO for Sunrise Medical (a durable medical equipment manufacturer).
Mr. Taglich is Co-Founder and President of Taglich Brothers, Inc., a New York-based investment bank which focuses on public and private micro-cap companies. Taglich Brothers was ranked Number One in investment performance for four years ending December 31, 2005. Mr. Taglich was a key contributor to the BioVentrix Series B round of financing, and also serves as Chairman of the Board for SCOLR Pharma, Inc.
“Michael and Warren each bring a unique competency to the BioVentrix Board,” said Kenneth Miller, BioVentrix President and CEO. “Michael and his group have been integral in supporting the development of breakthrough technology for Remote Ventricular Reduction. Warren is a visionary in the medical device industry and an expert in worldwide marketing strategy.”
“With these two appointments, the BioVentrix Board is now perfectly balanced, giving us the experience and depth to undertake the challenge of changing the way heart failure is treated,” concludes Miller.
The timing of the two additions to the Board was very strategic. BioVentrix will begin a pilot study for PliCath HF™ in Europe in mid-2008. PliCath HF is a catheter-based device intended to resize the left ventricle in heart failure patients with ischemic cardiomyopathy. The procedure is referred to as Remote Ventricular Reduction (RVR) and is done without having to put the patient on the heart lung perfusion machine. “PliCath HF will allow RVR to be performed using a minimally invasive technique, making it more accessible to the patients who need it most,” said Miller.
About BioVentrix
BioVentrix is a private corporation based in San Ramon, California. Its mission is to improve and expand on the surgical treatment of heart failure by left ventricular reconstruction, primarily through the development of less invasive approaches, and ultimately, catheter-based procedures. BioVentrix’s Scientific Advisory Board and associated physicians include some of the country’s leading surgeons and cardiologists. For more information, please visit www.bioventrix.com.